PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Consensus Rating of “Hold” by Analysts

PTC Therapeutics, Inc. (NASDAQ:PTCTGet Free Report) has earned a consensus recommendation of “Hold” from the fourteen analysts that are covering the company, Marketbeat.com reports. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $35.67.

Several analysts have issued reports on PTCT shares. TD Cowen lowered their price target on shares of PTC Therapeutics from $32.00 to $30.00 and set a “market perform” rating on the stock in a report on Friday, March 1st. Jefferies Financial Group boosted their price target on shares of PTC Therapeutics from $35.00 to $46.00 and gave the company a “buy” rating in a report on Monday, May 20th. JPMorgan Chase & Co. boosted their price target on shares of PTC Therapeutics from $43.00 to $53.00 and gave the company an “overweight” rating in a report on Tuesday, May 21st. Morgan Stanley upgraded shares of PTC Therapeutics from an “underweight” rating to an “equal weight” rating and boosted their price target for the company from $28.00 to $30.00 in a report on Monday, April 29th. Finally, Royal Bank of Canada boosted their price target on shares of PTC Therapeutics from $22.00 to $28.00 and gave the company a “sector perform” rating in a report on Friday, March 1st.

Get Our Latest Report on PTC Therapeutics

Insiders Place Their Bets

In other PTC Therapeutics news, Director Jerome B. Zeldis sold 20,000 shares of the business’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $38.24, for a total transaction of $764,800.00. Following the completion of the transaction, the director now owns 14,500 shares of the company’s stock, valued at approximately $554,480. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other PTC Therapeutics news, Director Jerome B. Zeldis sold 20,000 shares of the business’s stock in a transaction on Wednesday, May 22nd. The shares were sold at an average price of $38.24, for a total transaction of $764,800.00. Following the completion of the transaction, the director now owns 14,500 shares of the company’s stock, valued at approximately $554,480. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Matthew B. Klein sold 3,361 shares of the business’s stock in a transaction on Friday, April 19th. The stock was sold at an average price of $24.89, for a total transaction of $83,655.29. Following the transaction, the chief executive officer now directly owns 225,807 shares of the company’s stock, valued at approximately $5,620,336.23. The disclosure for this sale can be found here. Insiders sold a total of 24,849 shares of company stock valued at $888,907 in the last quarter. Insiders own 5.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Hexagon Capital Partners LLC raised its position in shares of PTC Therapeutics by 132.0% during the fourth quarter. Hexagon Capital Partners LLC now owns 979 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 557 shares during the last quarter. Diversified Trust Co raised its position in shares of PTC Therapeutics by 6.7% during the fourth quarter. Diversified Trust Co now owns 14,204 shares of the biopharmaceutical company’s stock valued at $391,000 after buying an additional 896 shares during the last quarter. Rhumbline Advisers raised its position in shares of PTC Therapeutics by 1.3% during the third quarter. Rhumbline Advisers now owns 107,004 shares of the biopharmaceutical company’s stock valued at $2,398,000 after buying an additional 1,322 shares during the last quarter. ProShare Advisors LLC raised its position in PTC Therapeutics by 9.3% in the first quarter. ProShare Advisors LLC now owns 18,313 shares of the biopharmaceutical company’s stock worth $533,000 after purchasing an additional 1,564 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC acquired a new position in PTC Therapeutics in the first quarter worth about $46,000.

PTC Therapeutics Stock Up 0.6 %

Shares of NASDAQ:PTCT opened at $35.62 on Wednesday. The company’s fifty day moving average is $32.84 and its two-hundred day moving average is $29.58. PTC Therapeutics has a 12-month low of $17.53 and a 12-month high of $44.66. The company has a market cap of $2.73 billion, a P/E ratio of -4.64 and a beta of 0.70.

PTC Therapeutics (NASDAQ:PTCTGet Free Report) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.21) by $0.01. The firm had revenue of $210.12 million for the quarter, compared to analyst estimates of $160.27 million. Equities research analysts anticipate that PTC Therapeutics will post -4.84 earnings per share for the current year.

About PTC Therapeutics

(Get Free Report

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.

Further Reading

Analyst Recommendations for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.